The origin of the prion agent of kuru: molecular and biological strain typing by Wadsworth, Jonathan D.F. et al.
Review
The origin of the prion agent of kuru:
molecular and biological strain typing
Jonathan D. F. Wadsworth, Susan Joiner, Jacqueline M. Linehan,
Emmanuel A. Asante, Sebastian Brandner and John Collinge*
MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology,
National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
Kuru is an acquired human prion disease that primarily affected the Fore linguistic group of the
Eastern Highlands of Papua New Guinea. The central clinical feature of kuru is progressive
cerebellar ataxia and, in sharp contrast to most cases of sporadic Creutzfeldt–Jakob disease (CJD),
dementia is a less prominent and usually late clinical feature. In this regard, kuru is more similar to
variant CJD, which also has similar prodromal symptoms of sensory disturbance and joint pains in
the legs and psychiatric and behavioural changes. Since a signiﬁcant part of the clinicopathological
diversity seen in human prion disease is likely to relate to the propagation of distinct human prion
strains, we have compared the transmission properties of kuru prions with those isolated from
patients with sporadic, iatrogenic and variant CJD in both transgenic and wild-type mice. These data
have established that kuru prions have prion strain properties equivalent to those of classical
(sporadic and iatrogenic) CJD prions but distinct from variant CJD prions. Here, we review these
ﬁndings and discuss how peripheral routes of infection and other factors may be critical modiﬁers of
the kuru phenotype.
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1. INTRODUCTION
Human prion diseases are fatal neurodegenerative
disorders that include Creutzfeldt–Jakob disease (CJD),
Gerstmann–Stra ¨ussler–Scheinker disease, fatal familial
insomnia, kuru and variant CJD (vCJD; Collinge 2001,
2005; Wadsworth & Collinge 2007). Their central
feature is the post-translational conversion of host-
encoded, cellular prion protein (PrP
C) to an abnormal
isoform, designated PrP
Sc (Prusiner 1982; Collinge
2001). Substantial evidence indicates that an abnormal
PrPisoformistheprincipal,ifnotthesole,componentof
the transmissible infectious agent, or prion (Prusiner
1982; Collinge 2001; Weissmann 2004; Collinge &
Clarke 2007). Human prion diseases are biologically
unique in that the disease process can be triggered
through inherited germ line mutations in the human
prionproteingene(PRNP),infection(byinoculation,or
in some cases by dietary exposure) with prion-infected
tissue or by rare sporadic events that generate
PrP
Sc (Collinge 2001, 2005; Wadsworth et al. 2003;
Wadsworth & Collinge 2007).
Human prion diseases are associated with a range of
clinical presentations and are classiﬁed by both
clinicopathological syndrome and aetiology with sub-
classiﬁcation according to molecular criteria (Collinge
1997, 2005; Collinge & Palmer 1997; Wadsworth et al.
2003). Approximately 85 per cent of cases occur
sporadically as CJD (sporadic CJD) at a rate of 1–2
cases per million population per year across the world,
with an equal incidence in men and women (Brown
et al. 1987; Collinge 2001, 2005; Wadsworth et al.
2003; Collins et al. 2006). Approximately 15 per cent
of human prion disease is associated with autosomal
dominant pathogenic PRNP mutations and to date
over 30 mutations have been described (Collinge 2001,
2005; Kovacs et al. 2002; Wadsworth et al. 2003; Mead
2006). Iatrogenic forms of prion disease have occurred
most frequently due to the transmission of CJD prions
via contaminated growth hormone derived from
human cadavers, or by implantation of contaminated
dura mater grafts (Brown et al. 1992, 2000). Iatrogenic
prion disease has also resulted from transmission of
CJD prions during corneal transplantation, contam-
inated electroencephalographic (EEG) electrode
implantation and surgical operations using contam-
inated instruments or apparatus (Brown et al. 1992,
2000). Acquired prion disease in humans due to a
dietary origin has resulted in kuru, an epidemic prion
disease principally of the Fore linguistic group of the
Eastern Highlands of Papua New Guinea, which was
transmitted during mortuary feasts when deceased
relatives were consumed by close relatives as a mark of
respect and mourning (Alpers 1987; Collinge & Palmer
1997; Mead et al. 2003), and vCJD in the United
Kingdom and other countries caused by human
exposure to BSE prions from cattle (Collinge et al.
1996; Bruce et al. 1997; Hill et al. 1997; Collinge 1999;
Asante et al. 2002). Kuru demonstrates that incubation
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50 years (Collinge et al. 2006) and these data indicate
that the parameters of any vCJD epidemic cannot yet
be predicted with conﬁdence (Collinge 1999; Frosh
et al. 2004; Hilton et al. 2004; Collinge et al. 2006).
Human PrP has a common polymorphism at residue
129 (encoding either methionine or valine) and
homozygosity confers genetic susceptibility to both
sporadic and acquired forms of CJD (Collinge et al.
1991; Palmer et al. 1991; Windl et al. 1996; Lee et al.
2001; Mead et al. 2003; Collins et al. 2006). The effect
of codon 129 is most strikingly observed invCJD where
all clinical cases studied so far have been methionine
homozygotes (Collinge 2005; Wadsworth & Collinge
2007). Codon 129 genotype also shows a pronounced
effect on kuru incubation periods and susceptibility
(Cervena ´kova ´ et al. 1999; Lee et al. 2001; Mead et al.
2003; Collinge et al. 2006) and the clear survival
advantage for PRNP codon 129 heterozygotes provides
a powerful basis for balancing selection in the Fore
where the majority of kuru-exposed survivors are
PRNP 129 heterozygotes (Mead et al. 2003).
The remarkable degree of clinical and neuropatho-
logical heterogeneity observed across the spectrum of
human prion disease has yet to be fully explained.
However, it has been clear for many years that distinct
isolates, or strains, of prions can be propagated in the
same host and these are biologically recognized by
distinctive clinical and pathological features in inocu-
lated laboratory animals (Collinge 2001; Hill &
Collinge 2001; Bruce 2003; Collinge & Clarke 2007).
It is therefore probable that a signiﬁcant proportion of
clinicopathological heterogeneity seen in human prion
diseases relates to the propagation of distinct human
prion strains (Collinge 2001; Collinge & Clarke 2007).
Genetic factors also inﬂuence prion strain selection
through the coding sequence of the host prion protein
gene (Collinge 1999, 2001; Hill & Collinge 2003;
Wadsworth et al. 2004; Collinge & Clarke 2007) and
other unknown non-PRNP genetic factors have also
been revealed (Stephenson et al. 2000; Lloyd et al.
2001, 2004a; Asante et al. 2002).
The origins of kuru have remained somewhat
obscure; however, in the absence of a pathogenic
PRNP mutation associated with kuru (Lee et al. 2001;
Mead et al. 2003), or any evidence for an animal origin,
the most plausible hypothesis for the source of kuru is
through chance consumption of an individual with
sporadic CJD (Alpers & Rail 1971). However, the
clinical features of kuru are remarkably stereotyped and
distinct from the majority of cases of sporadic CJD.
A prodrome and three clinical stages consisting of an
ambulatory stage, a sedentary stage and a tertiary stage
have been described in which progressive cerebellar
ataxia is the dominant clinical feature, with dementia
being a late and less prominent characteristic (Alpers
1987; Brown et al. 1994; Collinge & Palmer 1997;
Collinge 2005; Collinge et al. 2006). In this regard,
kuru is more reminiscent of variant CJD in which early
symptoms of peripheral sensory disturbance, joint
pains, psychiatric and behavioural changes are seen
prior to overt dementia (Collinge 2005; Collinge et al.
2006). Because clinicopathological diversity in human
prion diseases may relate to the propagation of different
prion strains, we have compared the transmission
properties of kuru prions with sporadic, iatrogenic
and variant CJD prions in transgenic and wild-type
mice. These data show that kuru prions are distinct
from vCJD prions and have molecular characteristics
and transmission properties closely similar to classical
CJD prions (Wadsworth et al. 2008). Here, we review
these ﬁndings and discuss their implications for under-
standing the clinicopathological phenotype of kuru.
2. MOLECULAR STRAIN TYPING STUDIES
Within the framework of the protein-only hypothesis of
prion propagation, the different phenotypes associated
with prion strains are thought to be determined by the
propagation of distinct PrP
Sc isoforms with divergent
physicochemical properties (Bessen & Marsh 1994;
Collinge et al. 1996; Telling et al. 1996; Prusiner
1998; Safar et al. 1998; Collinge 2001; Hill & Collinge
2001; Gambetti et al. 2003; Collinge & Clarke 2007).
To date, we have identiﬁed four major types of human
PrP
Sc associated with sporadic and acquired human
prion diseases that can be differentiated on immuno-
blots after limited proteinase K digestion of brain
homogenates (Collinge et al. 1996; Wadsworth et al.
1999; Hill et al. 2003). The different PrP fragment sizes
seen on immunoblots following treatment with protein-
ase K (corresponding to amino-terminally truncated
cleavage products generated from di-, mono- or non-
glycosylated PrP
Sc) suggest that there are several
different human PrP
Sc conformations, referred to as
molecular strain types and these can be further
classiﬁed by the ratio of the three PrP fragments seen
after protease digestion. PrP
Sc types 1–3 are seen in
classical (sporadic or iatrogenic) CJD brain, while type
4 PrP
Sc is uniquely seen in vCJD brain (Collinge et al.
1996; Wadsworth et al. 1999; Hill et al. 2003).
Polymorphism at human PrP residue 129 places
constraints upon the propagation of distinct human
PrP
Sc types and these data provide a molecular basis for
this polymorphism acting as a major factor inﬂuencing
both prion disease susceptibility and phenotype in
humans (Collinge 2001, 2005; Mead et al. 2003;
Wadsworth & Collinge 2007). To date, human PrP
Sc
types 1 and 4 have been found only in humans
homozygous for PRNP codon 129 methionine; type 3
PrP
Sc is seen almost exclusively in individuals with at
least one valine allele, while type 2 PrP
Sc has been
commonly observed in all codon 129 genotypes
(Collinge et al. 1996; Wadsworth et al. 1999; Hill
et al. 2003). A simpler molecular classiﬁcation of
classical CJD is also in use, based on subdivision into
only two molecular sub-types by fragment size (Parchi
et al. 1996, 1999). International agreement on
systematic classiﬁcation of molecular strain types in
human prion disease has not yet been achieved
(Wadsworth & Collinge 2007).
Recently, we have reported investigation of frontal
cortex brain samples from three neuropathologically
conﬁrmed patients with kuru (Wadsworth et al. 2008).
These isolates were provided by the late Dr Clarence J
Gibbs of the National Institutes of Health, Bethesda
MD, USA, and belonged to a cohort of 18 kuru patient
brain samples that were successfully transmitted to
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Health between 1963 and 1993 (Brown et al. 1994).
All patients in this series were reported to have the
usual stereotyped clinical progression of kuru with
progressive ataxia in the absence of early cognitive
impairment (Brown et al. 1994). Our analysis of these
isolates showed protease-resistant PrP fragment pat-
terns corresponding to either the type 2 or 3 PrP
Sc
pattern that we have observed in sporadic and
iatrogenic CJD (Wadsworth et al. 2008). Two patients
propagated type 3 PrP
Sc and were homozygous for
valine at PRNP codon 129; the other patient propa-
gated type 2 PrP
Scand was homozygous for methionine
at PRNP codon 129 (Wadsworth et al. 2008; ﬁgure 1).
The glycoform ratios of protease-resistant PrP frag-
ments in these kuru isolates were all similar to the PrP
glycoform ratios seen in classical CJD rather than the
distinctive PrP glycoform ratios seen in either vCJD or
inherited prion disease caused by PRNP point
mutations (Hill et al. 2003, 2006; Wadsworth et al.
2006; Wadsworth & Collinge 2007; ﬁgure 1). Collect-
ively, these data are consistent with the ﬁndings of
Gambetti and colleagues who have also reported close
similarity of the PrP
Sc types propagated in kuru and
classical CJD (Parchi et al. 1997, 2000).
3. TRANSMISSION RATES OF HUMAN PRIONS
IN TRANSGENIC AND WILD-TYPE MICE
Over the last 15 years, we have investigated the
transmission properties of prions from a cohort of
patients with neuropathologically conﬁrmed sporadic,
iatrogenic and variant CJD in transgenic mice expres-
sing only human PrP with either valine (V) or
methionine (M) at residue 129 and in wild-type mice
(Collinge et al. 1996;Hillet al. 1997;Asante et al. 2002,
2006; Wadsworth et al. 2004, 2008).
Transgenic mice expressing human PrP 129 valine,
but not mouse PrP (129VV Tg152 mice), lack a
transmission barrier to classical (sporadic and iatro-
genic) CJD prions, regardless of the codon 129
genotype of the inoculum (Collinge et al. 1995, 1996;
Hill et al. 1997; Wadsworth et al. 2008; ﬁgure 2). These
transmissions are characterized by approximately
100 per cent attack rates of prion infection producing
clinical prion disease with similar short incubation
periods of approximately 200 days (Collinge et al.
1995, 1996; Hill et al. 1997; Wadsworth et al. 2008;
ﬁgure 2). By contrast, primary challenge of 129VV
Tg152 mice with vCJD prions is characterized by a
substantial transmission barrier with only approxi-
mately 50 per cent of inoculated mice becoming
infected (Hill et al. 1997; Wadsworth et al. 2004,
2008; ﬁgure 2). Affected vCJD-inoculated Tg152 mice
propagate a novel prion strain associated with type 5
PrP
Sc (Hill et al. 1997; Wadsworth et al. 2004, 2008;
ﬁgure 3) which fails to adapt after secondary passage in
further 129VV Tg152 mice (Wadsworth et al. 2004).
In wild-type FVB/NHsd mice (genotype Prnp
a; Lloyd
et al. 2004b), the relative transmission efﬁciencies of
classical and variant CJD prions are quite different
(Collinge et al. 1995, 1996; Hill et al. 1997; Wadsworth
et al. 2004, 2008). Classical CJD prions transmit
infection to FVB/NHsd mice only occasionally, at long
and variable incubation periods, whereas vCJD prions
transmit infection far more efﬁciently, although incu-
bation periods are prolonged and variable (Hill et al.
1997; Asante et al. 2002; Wadsworth et al. 2004, 2008;
ﬁgure 2).
Recently, we reported that kuru prions have trans-
mission rates in 129VV Tg152 and FVB/NHsd mice
closely similar to those of classical CJD prions rather
than those of vCJD prions (Wadsworth et al. 2008;
ﬁgure 2). In 129VV Tg152 mice, kuru isolates produce
100 per cent attack rates of prion infection causing
clinical prion disease with closely similar mean incu-
bation periods of approximately 200 days (Wadsworth
et al. 2008; ﬁgure 2). In sharp contrast, no evidence for
prion infection is seen in kuru-inoculated FVB/NHsd
mice after prolonged observation periods (Wadsworth
et al. 2008; ﬁgure 2). These data are in agreement with
those of Brown and colleagues who showed that
experimental transmission rates of kuru prions in non-
human primates were also closely similar to classical
CJD isolates and distinct from inherited forms of prion
disease (Brown et al. 1994).
4. MOLECULAR AND NEUROPATHOLOGICAL
PHENOTYPES IN TRANSGENIC MICE
PROPAGATING HUMAN PRIONS
The hypothesis that alternative conformations or
assembly states of PrP provide the molecular substrate
for clinicopathological heterogeneity seen in human
prion diseases (and that this relates to the existence of
distinct human prion strains) has been strongly
supported by molecular and neuropathological analysis
of human prion transmissions to conventional and
transgenic mice. Transgenic mice expressing only
human PrP haveshownthat residue 129 polymorphism
constrains both the propagation of distinct human
PrP
Sc conformers and the occurrence of associated
patterns of neuropathology (Collinge et al. 1996; Hill
et al. 1997; Asante et al. 2002, 2006; Wadsworth et al.
2004, 2008; ﬁgure 3). Human PrP
Sc types 1 and 4
that are seen only in PRNP codon 129 methionine
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Figure 1. PrP
Sc strain types in human prion disease.
Immunoblots of proteinase K digested brain homogenates
from patients with human prion disease. Disease aetiology of
each brain sample is designated aboveeach lane and the PrP
Sc
type (using the London classiﬁcation of human PrP
Sc types;
Collinge et al. 1996; Hill et al. 2003, 2006) and PRNP codon
129 genotype of the patient (M, methionine; V, valine) are
designated below. Immunoblots were developed with anti-
PrP monoclonal antibody 3F4 using a chemiluminescent
substrate.
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129VV Tg152 mice. Type 1 PrP
Sc converts to a
PrP
Sc type with maintained glycoform ratio but a type
2 fragment size (Collinge et al. 1996) and type 4 PrP
Sc
converts to type 5 PrP
Sc with the same glycoform ratio
as type 4 PrP
Sc but a type 2 PrP
Sc-like fragment size
(Hill et al. 1997; Wadsworth et al. 2004; ﬁgure 3). By
contrast, in isolates examined to date, PrP
Sc types 2 and
3 appear to propagate faithfully in 129VV Tg152 mice
with no apparent change in proteolytic fragment size
(Collinge et al. 1996; Wadsworth et al. 2008). These
data are consistent with a conformational selection
model of prion transmission barriers (Collinge 1999,
2001; Hill & Collinge 2003; Wadsworth et al. 2004;
Collinge & Clarke 2007) and strongly support the
‘protein only’ hypothesis of prion infectivity by
suggesting that prion strain variation is encoded by a
combination of PrP conformation and glycosylation
(Collinge 2001; Collinge & Clarke 2007).
In agreement with the close similarities of both
PrP
Sc type and transmission rates of kuru prions and
classical CJD prions, type 3 PrP
Sc from kuru or sporadic
CJD brain propagated faithfully in 129VV Tg152 mice
(Wadsworth et al. 2008; ﬁgure 4). In these mice,
abnormal PrP deposition is characterized by a predom-
inantly diffuse pattern of PrP staining throughout the
thalamus and hypothalamus, occasionally accompanied
bysmallPrPplaquesinthecorpuscallosum(Wadsworth
et al. 2008). Interestingly, the same pattern of neuro-
pathology and the propagation of type 3 PrP
Sc was also
observedin129VVTg152miceinoculatedwith thetype
2P r P
Sc kuru isolate (Wadsworth et al. 2008; ﬁgure 4).
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Figure 2. Summary of rates of transmission of human prions
to transgenic and wild-type mice. Brain homogenate
from patients with neuropathologically conﬁrmed (a) kuru,
(b) iatrogenic CJD, (c) sporadic CJD and (d) variant CJD
were inoculated intra-cerebrally into transgenic mice
homozygous for a human PrP 129V transgene array
and murine PrP null alleles (Prnp
o/o)d e s i g n a t e d
Tg(HuPrP129V
C/C Prnp
o/o)-152 mice (129VV Tg152
mice; Collinge et al. 1995), and into wild-type FVB/NHsd
mice (genotype Prnp
a). The number of prion disease isolates
examined is designated below each schematic patient. Attack
rate is deﬁned as the total number of both clinically affected
and sub-clinically infected mice as a proportion of the
number of inoculated mice. In mice that were asymptomatic,
sub-clinical prion infection was assessed by immunoblotting
and/or immunohistochemical examination of brain. Primary
data are described in references (Collinge et al. 1995, 1996;
Hill et al. 1997; Wadsworth et al. 2004, 2008).
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Figure 3. Summary of transmission of vCJD prions to
transgenic mice expressing human PrP. Primary and
secondary transmission of vCJD prions in transgenic
Tg(HuPrP129M
C/C Prnp
o/o)-35 mice (Tg35) results in
faithful propagation of type 4 PrP
Sc and the occurrence of
abundant ﬂorid PrP plaques throughout the cortex which are
the neuropathological hallmark of vCJD. By contrast,
primary and secondary transmission of vCJD prions to
transgenic Tg(HuPrP129V
C/C Prnp
o/o)-152 mice (Tg152)
results in the propagation of a novel prion strain characterized
by type 5 PrP
Sc and the occurrence of large, non-ﬂorid PrP
plaques in the corpus callosum. (a) Representative immuno-
blots of proteinase K-treated brain homogenates from variant
CJD and transgenic mice analysed with anti-PrP monoclonal
antibody 3F4. The identity of the brain sample is designated
above each lane with the type of PrP
Sc present in the sample
designated below (using the London classiﬁcation of human
PrP
Sc types; Collinge et al. 1996; Hill et al. 2003; Wadsworth
et al. 2004). (b) Representative immunohistochemical
analysis of transgenic mouse brain showing abnormal PrP-
positive plaques stained with anti-PrP monoclonal antibody
3F4. Scale bar, 100 mm.
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behaviour of sub-types of sporadic CJD-like prions
associated with type 2 PrP
Sc and codon 129 methionine
when crossing a PRNP codon 129 transmission barrier;
however, further transmissions of CJD isolates with this
molecular strain type will be required to investigate this
directly (Wadsworth et al. 2008).
The pattern of neuropathology associated with the
propagation of type 3 PrP
Sc in 129VV Tg152 mice
contrasts sharply with that seen in vCJD-inoculated
129VV Tg152 mice propagating type 5 PrP
Sc.I nb o t h
clinically affected and sub-clinically infected 129VV
Tg152 mice, the propagation of type 5 PrP
Sc is only
accompanied by the occurrence of large, non-ﬂorid, PrP
plaques in the corpus callosum with an absence of PrP
plaques or diffuse PrP deposition in other brain areas
(Wadsworth et al. 2004, 2008; ﬁgure 4). Thus, kuru-
and sporadic CJD-inoculated 129VV Tg152 mice show
a closely similar pattern of neuropathology that is
distinct from the pattern seen in vCJD-inoculated mice.
5. DETERMINANTS OF KURU PHENOTYPE
Molecular and biological strain typing studies have
established that kuru prions havemolecular strain types
(Parchi et al. 1997, 2000; Wadsworth et al. 2008)a n d
transmission properties (Brown et al. 1994; Wadsworth
et al. 2008) equivalent to those of classical CJD prions
rather than vCJD prions or inherited forms of prion
disease. These data strongly support the hypothesis
that kuru originated from chance consumption of an
individual with sporadic CJD (Alpers & Rail 1971).
Despite the close molecular and biological similarity
of kuru prions and sporadic CJD prions, both the
clinical presentation and the neuropathology of kuru
are distinct from the majority of patients with sporadic
CJD. While rapidly progressive dementia is the deﬁning
clinical feature of approximately 70 per cent of cases of
sporadic CJD (Brown et al. 1987; Parchi et al. 1996,
1999; Collinge 2001, 2005; Hill et al. 2003; Wadsworth
et al. 2003; Collins et al. 2006), the central clinical
feature of kuru is progressive cerebellar ataxia with
dementia appearing as a late and less prominent feature
(Alpers 1987; Brown et al. 1994; Collinge & Palmer
1997; Collinge 2005; Collinge et al. 2006). Further-
more, although the neuropathological changes seen in
kuru lie within the spectrum of those seen in sporadic
CJD, unicentric PrP plaques are unusually prominent
and widespread (Hainfellner et al. 1997; McLean et al.
1998). Because a progressive cerebellar syndrome and
the occurrence of kuru-type plaques reminiscent of
kuru are also notable features of iatrogenic CJD
resulting from peripheral exposure to sporadic
CJD prions (Brown et al. 1992, 2000, 2006; Billette
de Villemeur et al. 1994; Will 2003), these observations
suggest that cerebellar onset and subsequent neuro-
pathological changes in kuru may be signiﬁcantly
determined by peripheral routes of infection (predom-
inantly dietary), rather than prion strain type. In this
context, although the clinical presentation of most
sporadic CJD patients is distinct from kuru, atypical
f o r m so fs p o r a d i cC J Da r ew e l lr e c o g n i z e d( Gomori
et al. 1973; Brown et al. 1984;P a r c h iet al. 1996, 1999;
Hill et al. 2003; Collins et al. 2006), and notably a
relatively rare sub-type of sporadic CJD associated
with long clinical duration and progressive ataxia also
shows prominent kuru-type PrP plaques (Parchi et al.
1996, 1999; Hill et al. 2003). As the aetiology of
sporadic CJD suggests involvement of a stochastic
p r o c e s ss u c ha ss o m a t i cPRNP mutation (Brown et al.
1987; Collinge 2001; Wadsworth et al. 2006; Mead
et al. 2007), it seems probable that part of the
phenotypic and neuropathological heterogeneity
seen in sporadic CJD may be related to peripheral
versus central initiation of prion replication. Clearly,
this might also be applicable in inherited forms of
prion disease where extensive phenotypic variability is
observed (Kovacs et al. 2002; Collinge 2005; Mead
2006; Wadsworth & Collinge 2007).
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Figure 4. Summary of molecular and neuropathological
phenotypes in transgenic mice. (a) Molecular strain typing of
human prion transmissions to mice. Immunoblots of
proteinase K-digested brain homogenates from human
patients or transgenic mice analysed by enhanced chemi-
luminescence with anti-PrP monoclonal antibody 3F4. The
provenance of each brain sample is designated above each
lane and the type of human PrP
Sc detected in each sample
(using the London classiﬁcation of human PrP
Sc types;
Collinge et al. 1996; Hill et al. 2003) is designated below.
(b) Neuropathological analysis of transgenic mouse brain. An
equivalent pattern of neuropathology is seen in 129VV Tg152
mice that propagate type 3 PrP
Sc following primary
transmission of kuru prions or sporadic CJD prions, which
is distinct from 129VV Tg152 mice that propagate type 5
PrP
Sc following primary transmission of vCJD prions.
Sketches represent the regional distribution of abnormal
PrP deposition in transgenic mouse brain visualized with
anti-PrP monoclonal antibody ICSM 35; bars, diffuse
synaptic PrP deposition and circles, PrP plaques.
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may also inﬂuence the neuropathology and clinical
features of kuru. Age is an important determinant of
survival in sporadic and inherited prion diseases
(Pocchiari et al. 2004; Mead et al. 2006) and the
marked difference in mean age of kuru and sporadic
CJD patients may account for some of the differences
that distinguish kuru from the majorityof sporadic CJD
cases. Genetic modiﬁers of prion disease may also be
important. A number of non-PRNP genetic loci that
exert a major inﬂuence on prion disease incubation
time have been mapped in mice (Stephenson et al.
2000; Lloyd et al. 2001). Although the genes respon-
sible for these mouse quantitative trait loci have not yet
been identiﬁed, their human orthologues may well play
a key role in phenotype determination and may be
polymorphic with signiﬁcant differences within and
between Europeans and the Fore.
We are most grateful to the late Dr Clarence J Gibbs and to
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